Cancer Research Journal
Volume 6, Issue 2, June 2018, Pages: 47-50
Received: Feb. 15, 2018;
Accepted: Mar. 1, 2018;
Published: Mar. 22, 2018
Views 973 Downloads 35
Qingsong Cao, Department of Otorhinolaryngology, The First Affiliated Hospital, Jinan University, Guangzhou, China
Jie Zhang, First Class Ward, The First Affiliated Hospital, Jinan University, Guangzhou, China
The aim of the current study was to evaluate the expression levels of STAT6, VEGF and microvessel density (MVD) score in nasal polyp tissues and to explore the underlying relationships during the pathogenesis of nasal polyps. 40 cases with surgical removal of nasal polyps were included, comparing with control group of 10 inferior turbinate mucosal tissues resected from nasal septum deviation correction surgery, from the same time period. By immunohistochemistry, the protein expression levels of STAT6, VEGF and MVD were determined. The results showed that the positive expression rate of STAT6 in mucosal epithelium and glands of nasal polyp tissues was 70%, which was significantly higher than that in control group (P < 0.01). The positive expression percentage of VEGF was 75%, which also higher than that in control group (P < 0.01). The MVD values in nasal polyp group was 22.67±7.54, while 7.04±2.63 in control group. The expression of STAT6 was closely related with the expression of VEGF and MVD, increasing with the level of VEGF and MVD. In general, the expression levels of STAT6, VEGF and MVD in nasal polyp group were increased and themselves were positively correlated, indicating the significant importance in the development of nasal polyp.
The Expression and Significance of STAT6, VEGF and MVD in Nasal Polyps, Cancer Research Journal.
Vol. 6, No. 2,
2018, pp. 47-50.
Sivasubramaniam, R. and R. J. Harvey, How to Assess, Control, and Manage Uncontrolled CRS/Nasal Polyp Patients. Curr Allergy Asthma Rep, 2017. 17(9): p. 58.
Hsu, J. and A. T. Peters, Pathophysiology of chronic rhinosinusitis with nasal polyp. Am J Rhinol Allergy, 2011. 25(5): p. 285-90.
Goenka, S. and M. H. Kaplan, Transcriptional regulation by STAT6. Immunol Res, 2011. 50(1): p. 87-96.
Yamaoka, K., K. Maeshima, S. Kubo, and Y. Tanaka, [Regulation of inflammation through JAK3-Stat6 pathway in dendritic cells]. Nihon Rinsho Meneki Gakkai Kaishi, 2012. 35(1): p. 62-8.
Li, B. H., S. B. Xu, F. Li, X. G. Zou, A. Saimaiti, D. Simayi, Y. H. Wang, Y. Zhang, J. Yuan, and W. J. Zhang, Stat6 activity-related Th2 cytokine profile and tumor growth advantage of human colorectal cancer cells in vitro and in vivo. Cell Signal, 2012. 24(3): p. 718-25.
Zafirellis, K., G. Agrogiannis, A. Zachaki, K. Gravani, A. Karameris, and C. Kombouras, Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res, 2008. 147(1): p. 99-107.
Slomka, M., O. Stasikowska, M. Wagrowska-Danilewicz, M. Danilewicz, and E. Malecka-Panas, [Diagnostic and prognostic values of repair protein hMLH1, hMSH2 and protein CD34 immunoexpression in sporadic colorectal cancer]. Pol Merkur Lekarski, 2010. 29(174): p. 351-6.
Kimura, H., T. Nakajima, K. Kagawa, T. Deguchi, M. Kakusui, T. Katagishi, T. Okanoue, K. Kashima, and T. Ashihara, Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver, 1998. 18(1): p. 14-9.
Kisseleva, T., S. Bhattacharya, J. Braunstein, and C. W. Schindler, Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene, 2002. 285(1-2): p. 1-24.
Wurster, A. L., T. Tanaka, and M. J. Grusby, The biology of Stat4 and Stat6. Oncogene, 2000. 19(21): p. 2577-84.
Lau, M., E. Tsantikos, M. J. Maxwell, D. M. Tarlinton, G. P. Anderson, and M. L. Hibbs, Loss of STAT6 promotes autoimmune disease and atopy on a susceptible genetic background. J Autoimmun, 2012. 39(4): p. 388-97.
Maier, E., A. Duschl, and J. Horejs-Hoeck, STAT6-dependent and -independent mechanisms in Th2 polarization. Eur J Immunol, 2012. 42(11): p. 2827-33.
Iyer, S. and K. R. Acharya, Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS J, 2011. 278(22): p. 4304-22.
Muluk, N. B., P. Atasoy, O. K. Arikan, and C. Koc, Role of vascular endothelial growth factor in the pathogenesis of nasal polyps. J Otolaryngol, 2007. 36(6): p. 357-66.
Park, S. K., H I. Kim, Y. I. Yang, and D. Y. Hur, Effects of methotrexate on vascular endothelial growth factor, angiopoietin 1, and angiopoietin 2 in nasal polyps. Am J Rhinol Allergy, 2011. 25(4): p. e129-32.
Wittekindt, C., A. Hess, W. Bloch, S. Sultanie, and O. Michel, Immunohistochemical expression of VEGF and VEGF receptors in nasal polyps as compared to normal turbinate mucosa. Eur Arch Otorhinolaryngol, 2002. 259(6): p. 294-8.
Lee, H. S., A. Myers, and J. Kim, Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis. Am J Respir Crit Care Med, 2009. 180(11): p. 1056-67.
Chen, Z. and Z. C. Han, STAT3: a critical transcription activator in angiogenesis. Med Res Rev, 2008. 28(2): p. 185-200.